Recent Research Analysts’ Ratings Changes for IDEXX Laboratories (IDXX)

IDEXX Laboratories (NASDAQ: IDXX) recently received a number of ratings updates from brokerages and research firms:

• 11/3/2026 – IDEXX Laboratories had its price target raised by UBS Group from $627.00 to $700.00. They now have a “neutral” rating on the stock.
• 11/3/2026 – IDEXX Laboratories had its price target raised by Morgan Stanley from $805.00 to $810.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – IDEXX Laboratories is no longer covered by BTIG Research. They set a “buy” rating on the stock.
• 10/27/2026 – IDEXX Laboratories had its price target lowered by UBS Group from $670.00 to $627.00. They now have a “neutral” rating on the stock.
• 10/20/2026 – IDEXX Laboratories had its price target lowered by Jefferies Financial Group from $795.00 to $705.00. They now have a “buy” rating on the stock.
• 10/16/2026 – IDEXX Laboratories is now covered by The Goldman Sachs Group. They set a “buy” rating and a $740.00 price target on the stock.
• 10/16/2026 – IDEXX Laboratories is now covered by The Goldman Sachs Group. They set a “buy” rating and a $740.00 price target on the stock.
• 10/16/2026 – IDEXX Laboratories had its price target lowered by JPMorgan Chase & Co. from $775.00 to $750.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – IDEXX Laboratories is now covered by KeyCorp. They set a “sector weight” rating on the stock.
• 10/8/2026 – IDEXX Laboratories was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.

IDEXX Laboratories Stock Performance

IDXX stock traded up $26.51 on Wednesday, reaching $698.55. The company’s stock had a trading volume of 1,019,114 shares, compared to its average volume of 579,919. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The company has a market capitalization of $55.03 billion, a P/E ratio of 47.10 and a beta of 1.55. The firm has a fifty day moving average of $538.81 and a two-hundred day moving average of $573.69. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter in the previous year, the business earned $3.22 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. As a group, analysts predict that IDEXX Laboratories, Inc. will post 15.05 EPS for the current fiscal year.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.